Latest Conference Articles

December 8th 2022, 7:19pm

San Antonio Breast Cancer Symposium

ARV-471 monotherapy elicited a significant clinical benefit rate in patients with estrogen receptor–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations.

December 8th 2022, 6:52pm

San Antonio Breast Cancer Symposium

Two separate doses of single-agent camizestrant monotherapy improved progression-free survival vs standard-of-care fulvestrant in patients with estrogen receptor-positive, HER2-negative advanced breast cancer.

December 8th 2022, 5:28pm

ESMO Immuno-Oncology Congress

Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.

December 8th 2022, 4:20pm

San Antonio Breast Cancer Symposium

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

December 8th 2022, 3:49pm

San Antonio Breast Cancer Symposium

The combination of capivasertib plus fulvestrant significantly improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive/HER2-negative advanced breast cancer, including those with AKT pathway–altered tumors.

December 8th 2022, 3:25pm

San Antonio Breast Cancer Symposium

The safety profile for the combination of tucatinib, trastuzumab, and capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic breast cancer.

December 8th 2022, 3:25pm

ESMO Immuno-Oncology Congress

Concurrent adagrasib and pembrolizumab produced preliminary activity when administered as first-line treatment in patients with non–small cell lung cancer harboring a KRAS G12C mutation, irrespective of PD-L1 status, according to data from the KRYSTAL-1 phase 1b and the KRYSTAL-7 phase 2 cohorts.

December 8th 2022, 3:36am

ESMO Immuno-Oncology Congress

Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer.

December 7th 2022, 11:45pm

San Antonio Breast Cancer Symposium

Sara A. Hurvitz, MD, discusses updated survival data with fam-trastuzumab deruxtecan-nxki in HER2-positive, unresectable/metastatic breast cancer.

December 7th 2022, 10:34pm

San Antonio Breast Cancer Symposium

Eribulin mesylate demonstrated a trend toward improved outcomes vs other chemotherapy options of physician’s choice in patients with HER2-low or HER2-0 metastatic breast cancer who were previously treated with at least 1 chemotherapy.

December 7th 2022, 9:58pm

San Antonio Breast Cancer Symposium

Patients with non-metastatic breast cancer undergoing treatment who added yoga to conventional exercises experienced improvements in disease-free survival, overall survival, and long-term quality of life vs those who did conventional exercises alone.

December 7th 2022, 9:05pm

San Antonio Breast Cancer Symposium

Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.

December 7th 2022, 8:50pm

San Antonio Breast Cancer Symposium

Neoadjuvant treatment with trastuzumab deruxtecan showed promising responses in patients with early-stage breast cancer.

December 7th 2022, 8:41pm

San Antonio Breast Cancer Symposium

Trastuzumab deruxtecan demonstrated a 64% reduction in the risk of disease progression or death compared with physician's choice of treatment in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who previously received ado-trastuzumab emtansine.

December 7th 2022, 4:50pm

San Antonio Breast Cancer Symposium

Ian Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

December 7th 2022, 3:52pm

The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, hormone receptor–positive breast cancer who would derive benefit from the addition of ovarian function suppression.

December 7th 2022, 2:30am

San Antonio Breast Cancer Symposium

Non-Hispanic Black patients with hormone receptor–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, according to an analysis of the phase 3 RxPONDER trial.

December 7th 2022, 12:58am

San Antonio Breast Cancer Symposium

A clinically meaningful improvement in invasive disease-free survival and distant relapse-free survival was observed with the addition of adjuvant abemaciclib to endocrine therapy in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer, according to results of a prespecified overall survival analysis of the monarchE study.

December 7th 2022, 12:46am

San Antonio Breast Cancer Symposium

The addition of 1 year of everolimus to adjuvant endocrine therapy did not demonstrate a statistically significant improvement in invasive disease-free survival or overall survival in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer.

December 6th 2022, 11:51pm

San Antonio Breast Cancer Symposium

The combination of ribociclib plus endocrine therapy yielded a 46% reduction in the risk of disease progression or death compared with chemotherapy in pre/perimenopausal patients with aggressive hormone receptor–positive/HER2-negative advanced breast cancer.